1
|
Yang S, Wang Q, Li T, Long J, Xiong Y, Feng L, Wang Q, Zhao Y, Yang J, Tang W, Zhang H, Qi L. Effectiveness of influenza vaccine among the population in Chongqing, China, 2018-2022: A test negative design-based evaluation. Hum Vaccin Immunother 2024; 20:2376821. [PMID: 39025479 PMCID: PMC11259055 DOI: 10.1080/21645515.2024.2376821] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2024] [Revised: 06/19/2024] [Accepted: 07/03/2024] [Indexed: 07/20/2024] Open
Abstract
Influenza vaccination is the most cost-effective strategy for influenza prevention. Influenza vaccines have been found to be effective against symptomatic and medically attended outpatient influenza illnesses. However, there is currently a lack of data regarding the effectiveness of inactivated influenza vaccines in Chongqing, China. We conducted a prospective observational test-negative design study. Outpatient and emergency cases presenting with influenza-like illnesses (ILI) and available influenza reverse transcription polymerase chain reaction (RT-PCR) were selected and classified as cases (positive influenza RT-PCR) or controls (negative influenza RT-PCR). A total of 7,307 cases of influenza and 7,905 control subjects were included in this study. The overall adjusted influenza vaccine effectiveness (IVE) was 44.4% (95% confidence interval (CI): 32.5-54.2%). In the age groups of less than 6 years old, 6-18 years old, and 19-59 years old, the adjusted IVE were 32.2% (95% CI: 10.0-48.9%), 48.2% (95% CI: 30.6-61.4%), and 72.0% (95% CI: 43.6-86.1%). The adjusted IVE for H1N1, H3N2 and B (Victoria) were 71.1% (95% CI: 55.4-81.3%), 36.1% (95% CI: 14.6-52.2%) and 33.7% (95% CI: 14.6-48.5%). Influenza vaccination was effective in Chongqing from 2018 to 2022. Evaluating IVE in this area is feasible and should be conducted annually in the future.
Collapse
Affiliation(s)
- Shuang Yang
- Infectious Disease Prevention and Control, Chongqing Municipal Center for Disease Control and Prevention, Chongqing, China
- School of Public Health, Chongqing Medical University, Chongqing, China
| | - Qing Wang
- Infectious Disease Prevention and Control, Chongqing Municipal Center for Disease Control and Prevention, Chongqing, China
- 2023 Key Disciplines on Public Health Construction in Chongqing, Chongqing, China
| | - Tingting Li
- Infectious Disease Prevention and Control, Chongqing Municipal Center for Disease Control and Prevention, Chongqing, China
- 2023 Key Disciplines on Public Health Construction in Chongqing, Chongqing, China
| | - Jiang Long
- Infectious Disease Prevention and Control, Chongqing Municipal Center for Disease Control and Prevention, Chongqing, China
- 2023 Key Disciplines on Public Health Construction in Chongqing, Chongqing, China
| | - Yu Xiong
- Infectious Disease Prevention and Control, Chongqing Municipal Center for Disease Control and Prevention, Chongqing, China
- 2023 Key Disciplines on Public Health Construction in Chongqing, Chongqing, China
| | - Luzhao Feng
- School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Qing Wang
- School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Yong Zhao
- School of Public Health, Chongqing Medical University, Chongqing, China
| | - Jule Yang
- Infectious Disease Prevention and Control, Chongqing Municipal Center for Disease Control and Prevention, Chongqing, China
- 2023 Key Disciplines on Public Health Construction in Chongqing, Chongqing, China
| | - Wenge Tang
- Infectious Disease Prevention and Control, Chongqing Municipal Center for Disease Control and Prevention, Chongqing, China
- 2023 Key Disciplines on Public Health Construction in Chongqing, Chongqing, China
| | - Huadong Zhang
- Infectious Disease Prevention and Control, Chongqing Municipal Center for Disease Control and Prevention, Chongqing, China
- 2023 Key Disciplines on Public Health Construction in Chongqing, Chongqing, China
| | - Li Qi
- Infectious Disease Prevention and Control, Chongqing Municipal Center for Disease Control and Prevention, Chongqing, China
- 2023 Key Disciplines on Public Health Construction in Chongqing, Chongqing, China
| |
Collapse
|
2
|
Zhang X, Yu H, Sun P, Huang M, Li B. Antiviral Effects and Mechanisms of Active Ingredients in Tea. Molecules 2024; 29:5218. [PMID: 39519859 PMCID: PMC11547931 DOI: 10.3390/molecules29215218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2024] [Revised: 10/24/2024] [Accepted: 11/01/2024] [Indexed: 11/16/2024] Open
Abstract
Viruses play a significant role in human health, as they can cause a wide range of diseases, from mild illnesses to severe and life-threatening conditions. Cellular and animal experiments have demonstrated that the functional components in tea, such as catechins, theaflavins, theanine, and caffeine, exhibit significant inhibitory effects on a diverse array of viruses, including influenza, rotavirus, hepatitis, HPV, and additional types. The inhibition mechanisms may involve blocking virus-host recognition, interfering with viral replication, enhancing host immune responses, and inhibiting viral enzyme activity. This article reviews the research progress on the antiviral effects of tea's functional components and their related mechanisms, hoping to contribute to future studies in this field.
Collapse
Affiliation(s)
- Xinghai Zhang
- Modern Service Industry Research Institute, Zhejiang Shuren University, Hangzhou, 310015, China;
| | - Haonan Yu
- Department of Tea Science, Zhejiang University, Hangzhou 310058, China; (H.Y.); (P.S.); (M.H.)
| | - Panjie Sun
- Department of Tea Science, Zhejiang University, Hangzhou 310058, China; (H.Y.); (P.S.); (M.H.)
| | - Mengxin Huang
- Department of Tea Science, Zhejiang University, Hangzhou 310058, China; (H.Y.); (P.S.); (M.H.)
| | - Bo Li
- Department of Tea Science, Zhejiang University, Hangzhou 310058, China; (H.Y.); (P.S.); (M.H.)
| |
Collapse
|
3
|
Jiang W, Lu C, Yan X, Tucker JD, Lin L, Li J, Larson HJ, Gong W, Wu D. Vaccine confidence mediates the association between a pro-social pay-it-forward intervention and improved influenza vaccine uptake in China: A mediation analysis. Vaccine 2024; 42:362-368. [PMID: 38103961 PMCID: PMC10789265 DOI: 10.1016/j.vaccine.2023.11.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2023] [Revised: 11/05/2023] [Accepted: 11/22/2023] [Indexed: 12/19/2023]
Abstract
INTRODUCTION A Chinese clinical trial has demonstrated that a prosocial pay-it-forward intervention that offered subsidized vaccination and postcard messages effectively increased influenza vaccine uptake and vaccine confidence. This secondary analysis explored the potential mediating role of vaccine confidence on the association between a pay-it-forward intervention and influenza vaccine uptake, and how this might vary by individual annual income levels. METHODS Data from 300 participants (150 standard-of-care and 150 pay-it-forward participants) were included in the analysis. We conducted descriptive analysis of demographic and vaccine confidence variables. Multivariable regression and mediation analysis on interventions, vaccine confidence and vaccine uptake were conducted. A sub-group analysis was conducted to further understand whether associations between these variables vary by income levels (<=$1860 or >$1860). RESULTS The pay-it-forward intervention was significantly associated with greater levels of perceived influenza vaccine importance (adjusted odds ratio (aOR) = 3.60, 95 %CI: 1.77-7.32), effectiveness (aOR = 3.37, 95 %CI: 1.75-6.52) and safety (aOR = 2.20, 95 %CI: 1.17-4.15). Greater perceived influenza vaccine importance was associated with increased vaccine uptake (aOR = 8.51, 95 %CI: 3.04-23.86). The indirect effect of the pay-it-forward intervention on vaccination was significant through improved perceived influenza vaccine importance (indirect effect1 = 0.07, 95 %CI: 0.02-0.11). This study further revealed that, irrespective of the individual income level, the pay-it-forward intervention was associated with increased vaccine uptake when compared to the standard-of-care approach. CONCLUSIONS Pay-it-forward intervention may be a promising strategy to improve influenza vaccine uptake. Perceived confidence in vaccine importance appears to be a potential mediator of the association between pay-it-forward and vaccine uptake.
Collapse
Affiliation(s)
- Wenwen Jiang
- West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China; School of Public Health of Nanjing Medical University, Nanjing, Jiangsu, China
| | - Chunlei Lu
- West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China; School of Public Health of Nanjing Medical University, Nanjing, Jiangsu, China
| | - Xumeng Yan
- University of North Carolina Project-China, Guangzhou, China; SESH (Social Entrepreneurship to Spur Health) Team, Guangzhou, China
| | - Joseph D Tucker
- SESH (Social Entrepreneurship to Spur Health) Team, Guangzhou, China; School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, Room 360, Keppel St, London WC1E 7HT, UK
| | - Leesa Lin
- Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK; Laboratory of Data Discovery for Health Limited (D24H), Hong Kong Science Park, Hong Kong Special Administrative Region; WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region
| | - Jing Li
- West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China
| | - Heidi J Larson
- Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK; Institute for Health Metrics and Evaluation, University of Washington, Seattle, USA
| | - Wenfeng Gong
- China Country Office of the Bill and Melinda Gates Foundation, China
| | - Dan Wu
- Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, Room 360, Keppel St, London WC1E 7HT, UK; Department of Social Medicine and Health Education, School of Public Health of Nanjing Medical University, Nanjing, Jiangsu, China.
| |
Collapse
|
4
|
Zhang J, Nian X, Liu B, Zhang Z, Zhao W, Han X, Ma Y, Jin D, Ma H, Zhang Q, Qiu R, Li F, Gong Z, Li X, Yang Y, Tian Y, Zhou L, Duan K, Li X, Ma Z, Yang X. Development of MDCK-based quadrivalent split seasonal influenza virus vaccine with high safety and immunoprotection: A preclinical study. Antiviral Res 2023; 216:105639. [PMID: 37270159 DOI: 10.1016/j.antiviral.2023.105639] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2023] [Revised: 04/12/2023] [Accepted: 05/17/2023] [Indexed: 06/05/2023]
Abstract
Vaccination remains the best prevention strategy against influenza. The MDCK-based influenza vaccine prompted the development of innovative cell culture manufacturing processes. In the present study, we report the effects of multiple administrations of a candidate, seasonal, MDCK-based, quadrivalent split influenza virus vaccine MDCK-QIV in Sprague-Dawley (SD) rats. Moreover, the effects of the vaccine were evaluated in terms of fertility and early embryonic development, embryo-fetal development, and perinatal toxicity in the SD rats and immunogenicity in Wistar rats and BALB/c mice. Regarding the safety profile, MDCK-QIV demonstrated tolerance in local stimulation with repeated dose administration and presented no significant effect on the development, growth, behavior, fertility, and reproductive performance of the adult male rats, maternal rats, and their offspring. MDCK-QIV elicited strong hemagglutination inhibition neutralizing antibody response and protection against the influenza virus in the mouse model. Thus, data supported that MDCK-QIV could be further evaluated in human clinical trial, which is currently underway.
Collapse
Affiliation(s)
- Jiayou Zhang
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Xuanxuan Nian
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Bo Liu
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Zhegang Zhang
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Wei Zhao
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Xixin Han
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Yumei Ma
- Lanzhou BaiLing Biotech Co., Ltd, 730010, Lanzhou, China
| | - Dongwu Jin
- Lanzhou BaiLing Biotech Co., Ltd, 730010, Lanzhou, China
| | - Hua Ma
- Lanzhou BaiLing Biotech Co., Ltd, 730010, Lanzhou, China
| | - Qingmei Zhang
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Ran Qiu
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Fang Li
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Zheng Gong
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Xuedan Li
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Ying Yang
- Hubei Topgene Biotechnology Co., Ltd, 430074, Wuhan, China
| | - Yichao Tian
- Hubei Topgene Biotechnology Co., Ltd, 430074, Wuhan, China
| | - Li Zhou
- Hubei Topgene Biotechnology Co., Ltd, 430074, Wuhan, China
| | - Kai Duan
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Xinguo Li
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Zhongren Ma
- Lanzhou BaiLing Biotech Co., Ltd, 730010, Lanzhou, China.
| | - Xiaoming Yang
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China; China National Biotec Group Company Limited, 100029, Beijing, China.
| |
Collapse
|
5
|
Li J, Zhang Y, Zhang X, Liu L. Influenza and Universal Vaccine Research in China. Viruses 2022; 15:116. [PMID: 36680158 PMCID: PMC9861666 DOI: 10.3390/v15010116] [Citation(s) in RCA: 29] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2022] [Revised: 12/23/2022] [Accepted: 12/27/2022] [Indexed: 01/03/2023] Open
Abstract
Influenza viruses usually cause seasonal influenza epidemics and influenza pandemics, resulting in acute respiratory illness and, in severe cases, multiple organ complications and even death, posing a serious global and human health burden. Compared with other countries, China has a large population base and a large number of influenza cases and deaths. Currently, influenza vaccination remains the most cost-effective and efficient way to prevent and control influenza, which can significantly reduce the risk of influenza virus infection and serious complications. The antigenicity of the influenza vaccine exhibits good protective efficacy when matched to the seasonal epidemic strain. However, when influenza viruses undergo rapid and sustained antigenic drift resulting in a mismatch between the vaccine strain and the epidemic strain, the protective effect is greatly reduced. As a result, the flu vaccine must be reformulated and readministered annually, causing a significant drain on human and financial resources. Therefore, the development of a universal influenza vaccine is necessary for the complete fight against the influenza virus. By statistically analyzing cases related to influenza virus infection and death in China in recent years, this paper describes the existing marketed vaccines, vaccine distribution and vaccination in China and summarizes the candidate immunogens designed based on the structure of influenza virus, hoping to provide ideas for the design and development of new influenza vaccines in the future.
Collapse
Affiliation(s)
| | | | | | - Longding Liu
- Key Laboratory of Systemic Innovative Research on Virus Vaccine, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China
| |
Collapse
|